Detroit Red Wings (8-10-2, in the Atlantic Division) vs. New York Islanders (8-8-5, in the Metropolitan Division) Elmont, New York; Monday, 7:30 p.m. EST BOTTOM LINE: The New York Islanders host the Detroit Red Wings after Kyle Palmieri scored two goals in the Islanders' 3-1 win against the St. Louis Blues. New York has an 8-8-5 record overall and a 3-3-2 record in home games. The Islanders have a 2-3-1 record when they commit more penalties than their opponent. Detroit is 8-10-2 overall and 4-5-1 on the road. The Red Wings have gone 3-3-2 in games their opponents serve fewer penalty minutes. The teams meet Monday for the third time this season. The Red Wings won the last meeting 2-1. TOP PERFORMERS: Bo Horvat has five goals and nine assists for the Islanders. Maxim Tsyplakov has over the last 10 games. Alex DeBrincat has eight goals and nine assists for the Red Wings. Albert Johansson has over the past 10 games. LAST 10 GAMES: Islanders: 4-3-3, averaging 2.7 goals, 4.7 assists, 2.6 penalties and 5.5 penalty minutes while giving up 2.6 goals per game. Red Wings: 4-5-1, averaging 2.2 goals, 3.5 assists, 2.2 penalties and 4.4 penalty minutes while giving up 2.5 goals per game. INJURIES: Islanders: None listed. Red Wings: None listed. The Associated Press created this story using technology provided by Data Skrive and data from Sportradar .Surgical Site Infections Therapeutics Market Size in the 7MM is expected to increase by 2034, estimates DelveInsight 12-23-2024 11:44 PM CET | Health & Medicine Press release from: ABNewswire DelveInsight's "Surgical Site Infections Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Surgical Site Infections, historical and forecasted epidemiology as well as the Surgical Site Infections market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. Discover Key Insights into the Surgical Site Infections Market with DelveInsight's In-Depth Report @ Surgical Site Infections Market Size [ https://www.delveinsight.com/sample-request/surgical-site-infections-ssi-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr ] Key Takeaways from the Surgical Site Infections Market Report * The Surgical Site Infections market size is anticipated to grow with a significant CAGR during the study period (2020-2034) * According to findings, surgical site infection occur in 2% to 4% of all patients undergoing inpatient surgical procedures. * Findings show that the overall incidence of surgical site infections was approximately 10% in the early 2000s, decreased to 7% by 2007, and further declined to 5% by 2020. * The leading Surgical Site Infections Companies such as MinaPharm Pharmaceuticals, Duke Clinical Research Institute, Zurex Pharma, Inc., Merck Sharp & Dohme LLC, Destiny Pharma Plc, PolyPid Ltd., GlaxoSmithKline, Durata Therapeutics, Cubist Pharmaceutical, Zurex Pharma, Inc., and others * Promising Surgical Site Infections Therapies such as Ciprodiazole, DFA-02 Antibiotic Gel, ZuraPrep, Ertapenem, XF-73, D-PLEX, cefuroxime, Dalbavancin, daptomycin, ZuraGard , and others Navigate the complexities of the Surgical Site Infections Market: gain insights into drug trends, treatment scenarios, and epidemiological data through our insightful Surgical Site Infections Market Forecast. Click here to get more insights @ Surgical Site Infections Treatment Market [ https://www.delveinsight.com/sample-request/surgical-site-infections-ssi-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr ] Surgical Site Infections Epidemiology Segmentation in the 7MM * Total Prevalence of Surgical Site Infections * Prevalent Cases of Surgical Site Infections by severity * Gender-specific Prevalence of Surgical Site Infections * Diagnosed Cases of Episodic and Chronic Surgical Site Infections Download the report to understand which factors are driving Surgical Site Infections epidemiology trends @ Surgical Site Infections Prevalence [ https://www.delveinsight.com/sample-request/surgical-site-infections-ssi-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr ] Surgical Site Infections Emerging Drugs * D-PLEX100: PolyPid D-PLEX is a new formulation of extended release of Doxycycline. D-PLEX is supplied as a sterile powder to be reconstituted to paste in the operating room, using standard aseptic techniques and is intended for single administration. The non-active components of the extended release antibiotic formulation are Tri-Calcium polymer and a lipid matrix. All formulation components are biodegradable. The company is conducting a Phase III, prospective, multinational, multicenter, randomized, controlled, two-arm, double blind study to assess efficacy and safety of D-PLEX administered concomitantly with the Standard of Care (SoC), compared to a SoC treated control arm, in prevention of post abdominal surgery incisional infection. * XF-73 Nasal gel: Destiny Pharma XF-73 Nasal gel, a dicationic porphyrin derivative, possesses strong bactericidal properties through a unique mechanism of action. It is a newly developed compound aimed at preventing Staphylococcal infections following surgical procedures. XF-73 Nasal gel is fast acting, requires very few applications and it has a very low propensity to develop bacterial resistance. Thus, XF-73 Nasal gel, preventing post-surgical infections, has the potential to reduce hospitalization stay, accelerate recovery and rehabilitation and improve quality of life for patients undergoing vital surgeries. In April 2024, Destiny Pharma disclosed audited results for 2023, announcing a strategic review to advance XF-73 nasal through Phase III trials. They also re-evaluated trial costs, developing a cost-effective design, and enhanced market understanding for partnerships. Surgical Site Infection Market Outlook The market for surgical site infection treatments is anticipated to grow significantly, driven by key players like PolyPid and Destiny Pharma, who are advancing their lead candidates through various clinical stages. PolyPid's D-PLEX100 and Destiny Pharma's XF-73, among other innovative therapies, aim to provide targeted and effective solutions for preventing and treating surgical site infection. The rising prevalence of surgical site infection, the increasing number of surgical procedures, and enhanced diagnostic technologies underscore the urgent need for advanced treatments. Get In-Depth Knowledge on Surgical Site Infections Market Trends and Forecasts with DelveInsight @ Surgical Site Infections Treatment Market [ https://www.delveinsight.com/sample-request/surgical-site-infections-ssi-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr ] Surgical Site Infections Therapies and Companies * Ciprodiazole: MinaPharm Pharmaceuticals * DFA-02 Antibiotic Gel: Duke Clinical Research Institute * ZuraPrep: Zurex Pharma, Inc. * Ertapenem: Merck Sharp & Dohme LLC * XF-73: Destiny Pharma Plc * D-PLEX: PolyPid Ltd. * cefuroxime: GlaxoSmithKline * Dalbavancin: Durata Therapeutics * daptomycin: Cubist Pharmaceutical * ZuraGard: Zurex Pharma, Inc. Surgical Site Infections Treatment Market Treatment for surgical site infections (SSIs) typically involves antibiotics tailored to the specific pathogens identified through wound cultures. The choice of antibiotics is crucial for effectively targeting the infection and reducing resistance. In some cases, if the infection does not respond to antibiotic therapy or if it involves deeper tissues or foreign materials, additional surgical intervention may be required to remove infected tissue, drain abscesses, or address complications. Prompt and appropriate management is essential to prevent the spread of infection, reduce recovery time, and minimize the risk of long-term complications. Gain a strategic edge in the Surgical Site Infections Market: explore comprehensive drug insights, treatment updates, and epidemiological forecasts in our in-depth Surgical Site Infections Market Forecast. Click here to lead in advancements @ Surgical Site Infections Clinical Trials Assessment [ https://www.delveinsight.com/sample-request/surgical-site-infections-ssi-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr ] Scope of the Surgical Site Infections Market Report * Study Period: 2020-2034 * Coverage: 7MM * Surgical Site Infections Companies: MinaPharm Pharmaceuticals, Duke Clinical Research Institute, Zurex Pharma, Inc., Merck Sharp & Dohme LLC, Destiny Pharma Plc, PolyPid Ltd., GlaxoSmithKline, Durata Therapeutics, Cubist Pharmaceutical, Zurex Pharma, Inc., and others * Surgical Site Infections Therapies: Ciprodiazole, DFA-02 Antibiotic Gel, ZuraPrep, Ertapenem, XF-73, D-PLEX, cefuroxime, Dalbavancin, daptomycin, ZuraGard, and others * Surgical Site Infections Therapeutic Assessment: Surgical Site Infections current marketed and Surgical Site Infections emerging therapies * Surgical Site Infections Market Dynamics: Surgical Site Infections market drivers and Surgical Site Infections market barriers * Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies * Surgical Site Infections Unmet Needs, KOL's views, Analyst's views, Surgical Site Infections Market Access and Reimbursement Table of Contents 1. Surgical Site Infections Market Report Introduction 2. Executive Summary for Surgical Site Infections 3. SWOT analysis of Surgical Site Infections 4. Surgical Site Infections Patient Share (%) Overview at a Glance 5. Surgical Site Infections Market Overview at a Glance 6. Surgical Site Infections Disease Background and Overview 7. Surgical Site Infections Epidemiology and Patient Population 8. Country-Specific Patient Population of Surgical Site Infections 9. Surgical Site Infections Current Treatment and Medical Practices 10. Surgical Site Infections Unmet Needs 11. Surgical Site Infections Emerging Therapies 12. Surgical Site Infections Market Outlook 13. Country-Wise Surgical Site Infections Market Analysis (2020-2034) 14. Surgical Site Infections Market Access and Reimbursement of Therapies 15. Surgical Site Infections Market Drivers 16. Surgical Site Infections Market Barriers 17. Surgical Site Infections Appendix 18. Surgical Site Infections Report Methodology 19. DelveInsight Capabilities 20. Disclaimer 21. About DelveInsight About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email:Send Email [ https://www.abnewswire.com/email_contact_us.php?pr=surgical-site-infections-therapeutics-market-size-in-the-7mm-is-expected-to-increase-by-2034-estimates-delveinsight ] Phone: 09650213330 Address:304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website: https://www.delveinsight.com/case-study/respiratory-domain-conference-coverage This release was published on openPR.0 peso 。

HEXstream and Oracle Optimizing Oracle Energy and Water Data IntelligenceIn conclusion, Indiana Jones and the Ancient Ring's achievement of reaching a peak of 12,000 concurrent players on Steam is a testament to its status as a standout title in the gaming industry. With its captivating storyline, engaging gameplay, and stunning presentation, the game has won the hearts of players around the world and continues to attract new fans with its exciting adventures and immersive world. Battling invaders in the world of Indiana Jones is indeed an exhilarating experience, and with the game's popularity soaring to new heights, it's clear that the legacy of Indiana Jones and the Ancient Ring will continue to endure for years to come.None

On the other hand, Lazio will approach the game with confidence and ambition, knowing that a win against Inter Milan could have far-reaching implications for the title race. With Marco Parolo pulling the strings in midfield and the team firing on all cylinders, Lazio will be eager to test Inter's resolve and push them into further crisis.Peter Andre captures Princess and baby Arabella's 'special sister bond' in heartwarming videoFeds announce permanent extension of asylum seeker work permits

News Stoinis named new Melbourne Stars BBL skipper The 35-year-old takes over from Glenn Maxwell who resigned at the end of last season after five years in the role Alex Malcolm 10-Dec-2024 • 1 hr ago Marcus Stoinis takes over as Melbourne Stars captain • Cricket Australia via Getty Images {"@context":"https://schema.org","@type":"ImageObject","contentUrl":"https://img1.hscicdn.com/image/upload/f_auto/lsci/db/PICTURES/CMS/373400/373404.1.jpg","caption":"Marcus Stoinis takes over as Melbourne Stars captain"} Marcus Stoinis has been confirmed as the new Melbourne Stars captain for the upcoming BBL season, replacing long-time skipper Glenn Maxwell who resigned at the end of last summer. Stoinis, 35, has led Stars once previously in Maxwell's absence last season. He had been a candidate to be interim captain when Maxwell missed the entire 2022-23 BBL season due to his broken leg but Stars opted to give the role to Adam Zampa. Stoinis is only the second player behind Maxwell to play 100 BBL matches for Stars and signed a three-year contract extension at the end of last season, meaning he will remain at the club until the end of 2026-27. Related Melbourne Stars sign Adam Milne for pre-Christmas BBL stint Injury hits Maxwell's Shield hopes, leaves race for BBL Stoinis said he was honoured to take over the role. "I had a little bit of a taste of captaining the side in Maxi's absence last year and loved the opportunity so to be given the role full-time is a great honour," Stoinis said. "The Stars have been such a constant in my life every summer for the last 10 years and I truly believe that the group we have assembled both on and off the field can bring some long overdue success to the club." Stars General Manager Blair Crouch acknowledged Maxwell's contribution as the leader over the past five seasons. "First of all, I want to acknowledge and thank Glenn Maxwell for all his efforts in leading the side over the past five seasons and he will continue to be a wonderful resource for everyone at the club," Crouch said. "Marcus demonstrated his leadership ability last year and has been a senior member of the side for a long time. "It's wonderful to have someone who has been at the Stars almost from our inception lead our club in BBL14." Stoinis is likely to lead a depleted line-up in the early part of the season. It is unknown when Maxwell will return from his hamstring injury but he seems unlikely to play in the first match of the season at least. Scott Boland and Beau Webster are also set to miss out while with Australia's Test squad. Overseas signings Ben Duckett and Osama Mir will also miss the first three games of the season. Meanwhile, Victoria duo Marcus Harris and Xavier Crone have been signed by Melbourne Renegades to complete their list for the upcoming BBL. Brisbane Heat have signed allrounder Jack Wildermuth in the final spot on their list. But Heat will add three local replacement players in the coming week with Michael Neser set to miss the early part of the season due to a hamstring injury, while Usman Khawaja and Marnus Labuschagne are unavailable until the end of the Australia-India Test series on January 8. Marcus Stoinis Glenn Maxwell Marcus Harris Xavier A Crone Michael Neser Melbourne Stars Big Bash League Alex Malcolm is an associate editor at ESPNcricinfo

None

GameStop Discloses Third Quarter 2024 ResultsDespite facing criticism at times for inconsistency in front of goal, Rashford's overall impact on the team cannot be understated. His work rate, dedication, and ability to perform under pressure have endeared him to both fans and teammates alike.

Arsenal's attacking prowess has been a key aspect of their identity over the years, with the club boasting a rich history of talented forwards and wingers who have dazzled fans with their skill and creativity. However, in recent seasons, the team has struggled to replicate the same level of performance in front of goal, particularly in open play situations.One of the main drivers of Europe's reliance on China is trade. China has become Europe's largest trading partner, with bilateral trade volumes reaching new highs year after year. European companies have benefited from access to China's market of over 1.4 billion increasingly affluent consumers, while Chinese companies have found Europe to be a lucrative market for their goods and services.

In addition to Totti, there are three other players who have reached the 600 appearances milestone in Serie A. These players, whose names may not be as widely recognized as Totti's, have nonetheless left an indelible mark on Italian football with their durability and consistency. Their dedication to the game and their clubs is a shining example of what it takes to achieve such a rare feat in the world of football.

SEASIDE — The City Council has appointed Christine Binnicker to fill the vacant Ward 1 position. City councilors publicly interviewed Binnicker, the director of state and local technology at consulting firm Guidehouse Inc., and Robin Montero, the chair of the Planning Commission, on Monday night to succeed Steve Dillard, who was recalled last summer. Dillard was targeted for recall over his advocacy for age restrictions at the Seaside Public Library. City Councilor David Posalski highlighted Binnicker’s wide experience working for a big city within a larger governmental organization. Binnicker, who moved to Seaside from Colorado over three years ago, has over 25 years of experience leading technology organizations for Denver. “I think we have kind of a choice between somebody who has a lot of experience in what we do and how we do it as a city in Robin, versus an outside perspective from Christine ... ,” Posalski said. “And I’ve seen a lot of the benefits that have come from bringing Spencer (Kyle) from a similar situation, having that outside view to bring in and enhance the things that we’re doing.” City Councilor Tita Montero, Robin Montero's sister-in-law , recused herself from the decision. Several city councilors expressed concerns over the optics of having two Monteros on the City Council, though they emphasized that they had full faith in both Tita Montero and Robin Montero to speak their minds independently. City Councilor Seth Morrisey said it would be one thing if voters elected Robin Montero, but that as city councilors making the decision, they must consider a public perspective. “Our system is set up in a way where, you know, we have seven councilors all elected from different wards,” he said. “And really, what we’re trying to do is spread out the power in a way where the public feels most represented.” Mayor Steve Wright described the appointment as “probably one of the hardest decisions we’ve ever had to make on the council. “As far as the idea, and again, you know, a lot of what we’ve been talking about — if you want to call it nepotism, or it’s just the way things appear — is an issue that people deal with pretty often, and particularly in really small towns ... I think Robin and Tita are both very independent people and won’t necessarily stand together on, you know, issues.” Wright and City Councilor Tom Horning initially wanted to appoint Montero, while Posalski, Morrisey and City Councilor Randy Frank opted for Binnicker. In the interest of having a unanimous vote, Wright and Horning changed their votes to reflect support for Binnicker, who was subsequently sworn into office. Binnicker told the City Council that she was honored and thrilled to take the position. “I’m excited for January to get going,” she said. “I have to give a little shout out to my inspiration, who is my mom, who is at home watching. And just, thank you, mom, because I’m here because of you.”